- Home
- AERT vs BOLD Comparison
AERT vs BOLD Comparison
Compare AERT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AERT
- BOLD
- Stock Information
- Founded
- AERT 2012
- BOLD 2018
- Country
- AERT Singapore
- BOLD United States
- Employees
- AERT N/A
- BOLD N/A
- Industry
- AERT Professional Services
- BOLD
- Sector
- AERT Consumer Discretionary
- BOLD
- Exchange
- AERT Nasdaq
- BOLD Nasdaq
- Market Cap
- AERT 25.4M
- BOLD 30.3M
- IPO Year
- AERT N/A
- BOLD 2024
- Fundamental
- Price
- AERT $0.66
- BOLD $1.12
- Analyst Decision
- AERT
- BOLD Buy
- Analyst Count
- AERT 0
- BOLD 3
- Target Price
- AERT N/A
- BOLD $4.00
- AVG Volume (30 Days)
- AERT 31.2K
- BOLD 79.1K
- Earning Date
- AERT 06-10-2025
- BOLD 05-09-2025
- Dividend Yield
- AERT N/A
- BOLD N/A
- EPS Growth
- AERT N/A
- BOLD N/A
- EPS
- AERT 0.47
- BOLD N/A
- Revenue
- AERT $70,851,000.00
- BOLD N/A
- Revenue This Year
- AERT N/A
- BOLD N/A
- Revenue Next Year
- AERT N/A
- BOLD N/A
- P/E Ratio
- AERT $1.40
- BOLD N/A
- Revenue Growth
- AERT 4.38
- BOLD N/A
- 52 Week Low
- AERT $0.46
- BOLD $1.06
- 52 Week High
- AERT $2.93
- BOLD $10.13
- Technical
- Relative Strength Index (RSI)
- AERT 49.98
- BOLD N/A
- Support Level
- AERT $0.55
- BOLD N/A
- Resistance Level
- AERT $0.68
- BOLD N/A
- Average True Range (ATR)
- AERT 0.05
- BOLD 0.00
- MACD
- AERT -0.00
- BOLD 0.00
- Stochastic Oscillator
- AERT 56.06
- BOLD 0.00
About AERT Aeries Technology Inc.
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.